DNK 333

Drug Profile

DNK 333

Latest Information Update: 24 Oct 2002

Price : $50

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Aza compounds; Benzamides
  • Mechanism of Action Neurokinin 1 antagonists; Neurokinin 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Rhinitis

Most Recent Events

  • 24 Oct 2002 Discontinued - Phase-II for Asthma (PO)
  • 24 Oct 2002 Discontinued - Phase-II for Chronic obstructive pulmonary disease (PO)
  • 24 Oct 2002 Discontinued - Phase-II for Rhinitis (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top